Search results for "Nicotinamide"

showing 10 items of 76 documents

Association between irisin and homocysteine in euglycemic and diabetic subjects

2014

Abstract Objectives The aim of study was to explore whether a relationship exists between homocysteine and irisin in type 2 diabetes (T2D) patients—a population with a high risk of developing cardiovascular disease—and euglycemic controls. Design and methods 69 T2D patients and 75 control subjects (adjusted by body mass index (BMI)) were included in the study. Irisin and homocysteine concentrations and anthropometric and biochemical variables were determined. Results Levels of homocysteine were significantly higher (11.0 ± 3.0 vs 12.4 ± 4.2 μmol/l) and levels of irisin were lower (279 ± 58 vs 263 ± 38 ng/ml) in T2D patients. When both T2D and controls were considered, irisin was found to co…

AdultBlood GlucoseMalemedicine.medical_specialtyHomocysteineClinical BiochemistryPopulationType 2 diabetesBody Mass Indexchemistry.chemical_compoundInternal medicineMyokineHumansInsulinMedicineClinical significanceeducationHomocysteineAgedCardiovascular risk factors Homocysteine Irisin Myokine NicotinamideAnalysis of Varianceeducation.field_of_studybusiness.industryFastingGeneral MedicineMiddle AgedAnthropometryControl subjectsmedicine.diseaseLipidsFibronectinsEndocrinologyDiabetes Mellitus Type 2chemistryFemalebusinessBody mass indexClinical Biochemistry
researchProduct

Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations

2015

Objective: The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role, with the disease activity, metabolic status and treatment modalities. Design: Data of 56 consecutive acromegalic patients (31 M and 25 F; aged 54 ± 12 years), admitted to the section of Endocrinology of the University of Palermo during the years 2005-2014, including 16 newly diagnosed untreated (ND), 21 during therapy with somatostatin analogues (SA), 12 with pegvisomant (PE) and 7 after surgical treatment (SU), grouped into uncontrolled (g…

AdultLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdipokineFatty Acids NonesterifiedSettore MED/13 - EndocrinologiaInsulin resistanceEndocrinologyAcromegaly; Adipokines; Growth hormone; Endocrinology; Endocrinology Diabetes and MetabolismAdipokinesInternal medicineAdipokineAcromegalyMedicineHumansNicotinamide PhosphoribosyltransferaseGrowth hormoneTriglyceridesAdiposityAgedLeptin receptorAdiponectinbusiness.industryLeptinCholesterol HDLMiddle Agedmedicine.diseaseEndocrinologyCross-Sectional StudiesPegvisomantAcromegalyCytokinesResistinFemaleInsulin ResistancebusinessBiomarkersmedicine.drug
researchProduct

Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome.

2009

Central fat distribution is increased in anovulatory women with polycystic ovary syndrome (PCOS) compared with ovulatory PCOS and matched controls. Among secreted adipocytokines, this is reflected mainly in lower levels of adiponectin.

AdultLeptinOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectAdipokineAdipose tissueBiologyAnovulationInsulin resistanceAdipokinesInternal medicinemedicineBody Fat DistributionHumansNicotinamide PhosphoribosyltransferaseOvulationmedia_commonAdiponectinLeptinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfat distribution; polycystic ovary syndromeLipidsfemale genital diseases and pregnancy complicationsEndocrinologyC-Reactive ProteinPhenotypeReproductive Medicinefat distributionCase-Control StudiesFemaleAdiponectinInsulin ResistanceWaist CircumferenceRetinol-Binding Proteins PlasmaAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Elevated peripheral visfatin levels in narcoleptic patients.

2008

OBJECTIVE: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients. METHODS: For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the Internatio…

AdultMalemedicine.medical_specialtyPolysomnographyNicotinamide phosphoribosyltransferaseAdipokineExcessive daytime sleepinesslcsh:MedicinePolysomnographyBody Mass IndexProinflammatory cytokineDiabetes and Endocrinology/Obesitychemistry.chemical_compoundReference ValuesInternal medicinemedicineHumansHLA-DR2 AntigenAge of OnsetNicotinamide Phosphoribosyltransferaselcsh:ScienceAgedNarcolepsySleep disorderMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RMiddle Agedmedicine.diseaseOrexinEndocrinologyMental Health/Sleep Disordersnervous systemchemistryImmunologyCytokinesFemalelcsh:Qmedicine.symptomImmunology/Genetics of the Immune SystembusinessResearch ArticleNarcolepsyPLoS ONE
researchProduct

Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels.

2012

N 1 -methylnicotinamide (MNA + ) has until recently been thought to be a biologically inactive product of nicotinamide metabolism in the pyridine nucleotides pathway. However, the latest observations imply that MNA + may exert antithrombotic and anti-inflammatory effects through direct action on the endothelium. We examined both in vivo and in vitro whether the compound might induce vasorelaxation in human blood vessels through the improvement of nitric oxide (NO) bioavailability and a reduction of oxidative stress mediated by endothelial NO synthase (eNOS) function. MNA + treatment (100 mg/m 2 orally) in healthy normocholesterolemic and hypercholesterolemic subjects increased the l-argini…

AdultNiacinamidemedicine.medical_specialtyEndotheliumBrachial ArteryNitric Oxide Synthase Type IIIHypercholesterolemiachemistry.chemical_elementCalciumIn Vitro Techniquesmedicine.disease_causeNitric OxideNitric oxidechemistry.chemical_compoundN^{1}-methylnicotinamideDouble-Blind MethodEnosnitric oxideInternal medicineInternal MedicinemedicineHumansflow-mediated dilationCalcimycinCells Culturedendothelial nitric oxide synthaseoxidized low-density lipoproteinbiologyDose-Response Relationship DrugChemistrySuperoxidebiology.organism_classificationendothelial cellsAcetylcholineOxygenVasodilationOxidative Stressmedicine.anatomical_structureEndocrinologysuperoxideEndothelium VascularAcetylcholineOxidative stressmedicine.drugLipoproteinHypertension (Dallas, Tex. : 1979)
researchProduct

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

2020

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg

Cancer ResearchGastroenterologypimasertiblaw.invention0302 clinical medicineRandomized controlled triallawClinical endpoint030212 general & internal medicineMalignant melanomaHazard ratioProgression-free survivalSciences bio-médicales et agricoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthDacarbazineOncology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030220 oncology & carcinogenesismedicine.symptomPimasertibmedicine.drugQuality of lifemedicine.medical_specialtyNauseaDacarbazinemalignant melanomadacarbazine[SDV.CAN]Life Sciences [q-bio]/CancerN-(2 3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNeutropeniaN-(23-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamidelcsh:RC254-282Article03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicinemedicineProgression-free survivalAdverse effectbusiness.industry[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.diseaseadverse eventsCancérologiequality of lifeAdverse events[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologybusinessprogression-free survival[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Copper(II)-phenylmalonate complexes with the bifunctional ligands nicotinamide and isonicotinamide

2011

Abstract The use as coligands of the nicotinamide (nia) and isonicotinamide (inia) molecules in the complex formation between copper(II) and phenylmalonate [Phmal = dianion of phenylmalonic acid] yielded the compounds of formula [Cu(inia)(Phmal)(H2O)] (1) and [Cu(inia)(Phmal)(H2O)]n (2). Although single crystals of 1 of appropriate size were grown, their unresolved twinning and space group ambiguity prevented a satisfactory X-ray structure determination. The crystal structure 2 consists of corrugated layers of copper(II) ions with intralayer carboxylate–phenylmalonate bridges in the anti-syn (equatorial-apical) coordination mode. A water molecule and the isonicotinamide group are coordinate…

DenticityLigandCoordination polymerchemistry.chemical_elementCrystal structureCrystal engineeringCopperInorganic Chemistrychemistry.chemical_compoundCrystallographychemistryMaterials ChemistryIsonicotinamidePhysical and Theoretical ChemistryIsostructuralPolyhedron
researchProduct

Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1

2014

Abstract Mitochondrial dysfunctions accompany several neurodegenerative disorders and contribute to disease pathogenesis among others in Parkinson’s disease (PD). Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a major regulator of mitochondrial functions and biogenesis, and was suggested as a therapeutic target in PD. PGC-1α is regulated by both transcriptional and posttranslational events involving also the action of growth factors. Fibroblast growth factor-21 (FGF21) is a regulator of glucose and fatty acid metabolism in the body but little is known about its action in the brain. We show here that FGF21 increased the levels and activity of PGC-1α and elevated mito…

FGF21educationRegulatorNicotinamide phosphoribosyltransferasePGC-1αFGF21; PGC-1α; SIRT1; Dopaminergic neurons; Mitochondria; Parkinson’s diseaseMitochondrionBioinformaticsDopaminergic neuronsSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundFGF21SIRT10302 clinical medicineDopaminergic Cell030304 developmental biologyDopaminergic neuron0303 health sciencesMultidisciplinarybiologySirtuin 1ResearchDopaminergicMitochondriaCell biologychemistryParkinson’s diseasebiology.protein3111 BiomedicineNAD+ kinase030217 neurology & neurosurgerySpringerPlus
researchProduct

Nicotinamide fumaric acid supramolecular cocrystals: diversity of stoichiometry

2009

Synthesis of nicotinamide and fumaric acid supramolecular cocrystals with 1 : 1 and 2 : 1 amide to acid stoichiometries results in the formation of an amide–acid heterosynthon (1 : 1 stoichiometry) and an amide–amide homosynthon (2 : 1 stoichiometry) and different conformations of the fumaric acid moieties.

Fumaric acidchemistry.chemical_compoundNicotinamideChemistryAmideSupramolecular chemistryOrganic chemistryGeneral Materials ScienceGeneral ChemistryCondensed Matter PhysicsStoichiometryCrystEngComm
researchProduct

Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice

2014

Objective: The C57Bl/6J (Bl/6J) mouse is the most widely used strain in metabolic research. This strain carries a mutation in nicotinamide nucleotide transhydrogenase (Nnt), a mitochondrial enzyme involved in NADPH production, which has been suggested to lead to glucose intolerance and beta-cell dysfunction. However, recent reports comparing Bl/6J to Bl/6N (carrying the wild-type Nnt allele) under normal diet have led to conflicting results using glucose tolerance tests. Thus, we assessed glucose-stimulated insulin secretion (GSIS), insulin sensitivity, clearance and central glucose-induced insulin secretion in Bl/6J and N mice using gold-standard methodologies. Methods: GSIS was measured u…

Genetically modified mouseFSIVGTT frequently sampled intravenous glucose tolerance testmedicine.medical_specialtylcsh:Internal medicineinsulin secretionNormal dietDI disposition indexOGTT oral glucose tolerance testmedicine.medical_treatment[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionbeta-cellBrief Communicationmedicine.disease_cause[ SDV.BA ] Life Sciences [q-bio]/Animal biologyGSIS glucose-stimulated insulin secretiongenetic backgroundGIR glucose infusion rateInternal medicinemedicineInsulin-degrading enzymeIDE insulin degrading enzymeFood and Nutritioninsulin sensitivityInsulin secretionlcsh:RC31-1245Molecular BiologyEndocrinology and metabolismMutationMI insulin sensitivity indexbusiness.industryInsulin[SDV.BA]Life Sciences [q-bio]/Animal biologyInsulin sensitivityCell BiologyNNT nicotinamide nucleotide transhydrogenaseEndocrinologyIVGTT intravenous glucose tolerance testAlimentation et NutritionEndocrinologie et métabolismemouse strainBeta cellbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionbeta-cell;insulin secretion;insulin sensitivity;genetic background;mouse strain
researchProduct